1 / 4

Analysis of Differentially Expressed Proteins in MCF7 and LCC1 Cells via LC-MS

This document provides a comprehensive overview of LC-MS analysis of myc-interacting proteins in MCF7 and LCC1 cells. It includes supplemental tables detailing differentially expressed proteins under various treatment conditions. Tables S1, S2, and S3 highlight proteins from MCF7, LCC1, and LCC1 EGF-treated cells, respectively, with key differentials marked in red. Additionally, Table S4 presents clinical trials investigating the efficacy of trastuzumab in patients with HER2-low/negative breast cancer, exploring therapeutic implications for these cohorts.

emma-wood
Télécharger la présentation

Analysis of Differentially Expressed Proteins in MCF7 and LCC1 Cells via LC-MS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Table S1 Complete list of LC-MS myc interating protiens in the MCF7 cells, proteins highlighted in red are those differentially expressed from the LCC1 and LCC1 EGF treated cells.

  2. Supplemental Table S2 Complete list of LC-MS myc interating protiens in the LCC1 cells, proteins highlighted in red are those differentially expressed from the LCC1 EGF and MCF7 cells

  3. Supplemental Table S3 Complete list of LC-MS myc interating protiens in the LCC1 EGF treated cells, proteins highlighted in red are those differentially expressed from the LCC1 and MCF7 cells

  4. Supplemental Table S4 Clinical trials examining the potential benefit of trastuzumab in Her2 low/Her2 negative breast cancer patients

More Related